Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478

被引:83
作者
Johns, TG
Luwor, RB
Murone, C
Walker, F
Weinstock, J
Vitali, AA
Perera, RM
Jungbluth, AA
Stockert, E
Old, LJ
Nice, EC
Burgess, AW
Scott, AM
机构
[1] Austin Hosp, Ludwig Inst Canc Res, Heidelberg, Vic 3084, Australia
[2] Royal Melbourne Hosp, Ludwig Inst Canc Res, Parkville, Vic 3050, Australia
[3] Mem Sloan Kettering Canc Ctr, Ludwig Inst Canc Res, New York, NY 10021 USA
关键词
D O I
10.1073/pnas.2036503100
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Blockade of epidermal growth factor receptor (EGFR) signaling with specific inhibitors of the EGFR tyrosine kinase retards cellular proliferation and arrests the growth of tumor xenografts. AG1478, an inhibitor of the EGFR tyrosine kinase, is used in laboratory studies; however, its therapeutic potential has not been elucidated. Therefore, we evaluated an aqueous form of AG1478 for its antitumor activity in mice bearing human xenografts expressing the WT EGFR or a naturally occurring ligand-independent truncation of the EGFR [delta2-7 (de2-7) EGFR or EGFRvIII]. Parenteral administration of soluble AG1478 blocked phosphorylation of the EGFR at the tumor site and inhibited the growth of A431 xenografts that overexpress the WT EGFR and glioma xenografts expressing the de2-7 EGFR. Strikingly, even subtherapeutic doses of AG1478 significantly enhanced the efficacy of cytotoxic drugs, with the combination of AG1478 and temozolomide displaying synergistic antitumor activity against human glioma xenografts. AG1478 was also examined in combination with mAb 806, an anti-EGFR antibody that was raised against the de2-7 EGFR but unexpectedly also binds a subset of the EGFR expressed in cells exhibiting amplification of the EGFR gene. The combination of AG1478 and mAb 806 displayed additive, and in some cases synergistic, antitumor activity against tumor xenografts over-expressing the EGFR. Here, we demonstrate that different classes of inhibitors to the EGFR can have synergistic antitumor activity in vivo. These results establish the antitumor efficacy of the EGFR inhibitor AG1478 and provide a rationale for its clinical evaluation in combination with both chemotherapy and other EGFR therapeutics.
引用
收藏
页码:15871 / 15876
页数:6
相关论文
共 31 条
[1]   Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia [J].
Arteaga, CL .
SEMINARS IN ONCOLOGY, 2002, 29 (05) :3-9
[2]   Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site [J].
Arteaga, CL ;
Ramsey, TT ;
Shawver, LK ;
Guyer, CA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (37) :23247-23254
[3]   Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family [J].
Bishop, PC ;
Myers, T ;
Robey, R ;
Fry, DW ;
Liu, ET ;
Blagosklonny, MV ;
Bates, SE .
ONCOGENE, 2002, 21 (01) :119-127
[4]  
Bos M, 1997, CLIN CANCER RES, V3, P2099
[5]  
Ciardiello F, 2000, CLIN CANCER RES, V6, P2053
[6]   The ErbB receptor family: a therapeutic target for cancer [J].
de Bono, JS ;
Rowinsky, EK .
TRENDS IN MOLECULAR MEDICINE, 2002, 8 (04) :S19-S26
[7]  
DeWitt AE, 2001, J CELL SCI, V114, P2301
[8]   High-performance liquid chromatographic analysis of the tyrphostin AG1478, a specific inhibitor of the epidermal growth factor receptor tyrosine kinase, in mouse plasma [J].
Ellis, AG ;
Nice, EC ;
Weinstock, J ;
Levitzki, A ;
Burgess, AW ;
Webster, LK .
JOURNAL OF CHROMATOGRAPHY B, 2001, 754 (01) :193-199
[9]  
Friedman HS, 2000, CLIN CANCER RES, V6, P2585
[10]  
Han YC, 1996, CANCER RES, V56, P3859